Sex differences help precision medicine
In her review of Gina Rippon's book The Gendered Brain, Lise Eliot uses the term "neurosexism" to describe the "myth" of brain differences in men and women (Nature 566, 453-454; 2019) . Although the field is indeed rife with misinterpretation and methodological flaws, that is no justification for dismissing sex differences in neuroscience (see also R. Voskuhl and S. Klein Nature 568, 171; 2019).
A variety of neurological and psychiatric conditions demonstrate robust differences between the sexes in their incidence, symptoms, progression and response to treatment (see, for example, M. T. Ferretti et al. Nature Rev. Neurol. 14, 457-469; 2018 Your criticism is based on the absence of double-blind studies for this treatment. But in this therapy, known as Stemirac, stem cells from the patient's bone marrow are cultured externally and then returned to the patient. A double-blind study is therefore structurally impossible, and performing a sham operation on a control group would raise ethical issues.
In such cases, properly designed clinical studies can still test efficacy -as demonstrated for drugs approved by the US Food and Drug Administration as well as in Japan. Given the convincing response to Stemirac by the group of paralysed people under discussion, it could be unethical to withhold approval and deny treatment. The rationale for the safety, efficacy and quality of the product, and for the ethics of its approval, is given in the evaluation report by Japan's Pharmaceuticals and Medical Devices Agency (see go.nature. com/2uzyqk9; in Japanese).
You also criticize Japan for marketing products with 'questionable' efficacy and for making patients bear the costs of clinical studies. However, under the terms of the country's conditional and time-limited approval for regenerative medical products, such products are granted marketing authorization only when efficacy can be demonstrated in post-marketing studies within a specified period. 
